Drug Profile
Thiotepa - Adienne
Alternative Names: Tepadina; ThioplexLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator ADIENNE
- Developer ADIENNE; Amneal Pharmaceuticals; ESTEVE Pharmaceuticals; Gruppo Italiano Trapianto di Midollo Osseo
- Class Antineoplastics; Aziridines; Myeloablative agonists; Organothiophosphorus compounds
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Adenocarcinoma; Cancer metastases; Graft-versus-host disease; Haematological disorders; Lymphoma; Papilloma; Solid tumours
- No development reported Brain cancer
Most Recent Events
- 17 Sep 2020 No recent reports of development identified for phase-II development in Brain cancer (Combination therapy, In adolescents, In children, In infants, In neonates) in Japan (IV) (UMIN000026084)
- 17 Sep 2020 No recent reports of development identified for phase-II development in Graft-versus-host disease (Prevention) in Italy (IV) (NCT01814488)
- 11 May 2020 CASI Pharmaceuticals plans a registrational trial for Haematological malignancies and Inherited blood disorders in China by 2021 (IV)